Genetically engineered parasites: The solution to designing an effective malaria vaccine?

Trends in Parasitology

Volumn 26, Issue 7, 2010, Pages 322-323

  Fitchett, Joseph R ^a   Cooke, Mary K ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; MALARIA VACCINE; PROTEIN P52; LIVE VACCINE;

DNA MODIFICATION; DRUG DESIGN; GENE DELETION; GENETIC ENGINEERING; IMMUNE RESPONSE; INFECTION CONTROL; MALARIA; PLASMODIUM (LIFE CYCLE STAGE); PLASMODIUM FALCIPARUM; PROPHYLAXIS; SHORT SURVEY; ANIMAL; GENETICS; HUMAN; IMMUNOLOGY; MALARIA, FALCIPARUM; PARASITOLOGY; TRANSGENIC ORGANISM;

ANIMALS; HUMANS; MALARIA VACCINES; MALARIA, FALCIPARUM; ORGANISMS, GENETICALLY MODIFIED; PLASMODIUM FALCIPARUM; VACCINES, ATTENUATED;

PLASMODIUM FALCIPARUM;

EID: 77953960110     PISSN: 14714922     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pt.2010.04.008     Document Type: Short Survey

References (23)

1. Guerra C.A., et al. The limits and intensity of Plasmodium falciparum transmission: implications for malaria control and elimination worldwide. PLoS Med. 2008, 5:38. doi:10.1371/journal.pmed.0050038.
2. Greenwood B.M. Control to eliminations: implications for malaria research. Trends Parasitol. 2008, 24:449-454.
3. Samarasekera U. Countries race to contain resistance to key antimalarial. Lancet 2009, 374:277-280.
4. Druilhe P., Barnwell J.W. Pre-erythrocytic stage malaria vaccines: time for a change in path. Curr. Opin. Microbiol. 2007, 10:371-378.
5. Gordon D.M., et al. Safety, immunogenicity, and efficacy of a recombinantly produced Plasmodium falciparum circumsporozoite protein-hepatitis B surface antigen subunit vaccine. J. Infect. Dis. 1996, 171:1576-1585. http://www.jstor.org/pss/30135583.
6. Stoute J.A., et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N. Engl. J. Med. 1997, 336:86-91. http://content.nejm.org/cgi/content/short/336/2/86.
7. Kester K.E., et al. Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. J. Infect. Dis. 2001, 183:640-647.
8. Bojang K.A., et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 2001, 358:1927-1934.
9. Alonso P.L., et al. Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet 2004, 364:1411-1420.
10. Aponte J.J., et al. Safety of the RTS,S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. Lancet 2007, 370:1543-1551.
11. Greenwood B. Can malaria be eradicated?. Trans. R. Soc. Trop. Med. Hyg. 2009, 103:S2-5.
12. VanBuskirk K.M., et al. Pre-erythrocytic, live attenuated Plasmodium falciparum vaccine candidates by design. PNAS 2009, 106:13004-13009.
13. Nussenzweig R.S., et al. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 1967, 216:160-162.
14. Mueller A.K., et al. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 2005, 433:164-167.
15. Labaied M., et al. Plasmodium yoelii sporozoites with simultaneous deletion of P52 and P36 are completely attenuated and confer sterile immunity against infection. Infect. Immun. 2007, 75:3758-3768.
16. Vaughan A.M., et al. Genetically engineered, attenuated whole-cell vaccine approaches for malaria. Hum. Vaccines 2010, 6:107-113. http://eurekah.com/journals/vaccines/article/9654/.
17. Sacci J.B., et al. Int. J. Parasitol. 2006, 36:353-360.
18. Weiss W.R., et al. CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. PNAS 1988, 85:573-576.
19. + T lymphocytes is required for protective immunity against Plasmodium berghei. J. Immunol. 1996, 156:3374-3381.
20. Bejon P., et al. Efficacy of RTS,S/AS02E vaccine against malaria in children 5 to 17 months of age. N. Engl. J. Med. 2008, 359:2521-2532.
21. Abdulla S. Safety and immunogenicity of RTS,S/AS02D malaria vaccine in infants. N. Engl. J. Med. 2008, 359:2533-2544.
22. Collins W.E., Barnwell J.W. A hopeful beginning for malaria vaccines. N. Engl. J. Med. 2008, 359:2599-2601.
23. Arevalo-Herrera M., et al. Current status of Plasmodium vivax vaccine. Hum. Vaccines 2010, 6:124-132. http://eurekah.com/journals/vaccines/article/9931/.